|
|
|
[unknown placeholder $cat.num$] Last Updated: Mar 19, 2007 - 3:12:58 AM |
Public Companies
:
Healthcare/BioTech
Antisoma licenses rights to develop Betagenon's AMPK activators as cancer treatments
LONDON -- (MARKET WIRE) -- 04/14/08 --
Apr 14, 2008 - 1:36:01 AM
Public Companies
:
Healthcare/BioTech
Galapagos appoints Piet Wigerinck as Senior VP Development
MECHELEN, BELGIUM -- (MARKET WIRE) -- 04/14/08 --
Apr 14, 2008 - 1:36:01 AM
Public Companies
:
Healthcare/BioTech
Marshall Edwards, Inc.'s Investigational Drug Triphendiol (NV-196) Demonstrates Potent Activity Against Biliary Cancers
SAN DIEGO, CA -- (MARKET WIRE) -- 04/13/08 -- Pre-clinical studies presented here today atthe annual meeting of the American Association for Cancer Researchdemonstrate that Marshall Edwards, Inc.'s investigational drug candidatetriphendiol (NV-196) induces apoptosis in pancreatic and bile duct cancercell lines, and also retards tumor proliferation in animal models of bothindications. Of significance, triphendiol also potently sensitizespancreatic and bile duct cancer cell lines and xenograft tumors to thestandard of care drug, gemcitabine. These data were presented by EwanTytler, PhD, Assistant Professor, Division of General Surgery,Gastroinstestinal Section, University of Alabama at Birmingham (UAB), aspart of a "late breaking" poster session.
Apr 13, 2008 - 3:36:01 PM
Public Companies
:
Healthcare/BioTech
Savaria Declares a Dividend
LAVAL, QUEBEC -- (MARKET WIRE) -- 04/11/08 -- The Board of directors of Savaria Corporation (TSX: SIS), the second largest company in the accessibility equipment industry in North America, has declared a dividend of 6.3 cents ($0.063) per common share to be paid on May 6, 2008 to shareholders of record on April 22, 2008.
Apr 11, 2008 - 2:36:01 PM
Public Companies
:
Healthcare/BioTech
Bio-Rad to Report First-Quarter 2008 Financial Results Tuesday, May 6, 2008
HERCULES, CA -- (MARKET WIRE) -- 04/11/08 -- Bio-Rad Laboratories, Inc. (AMEX: BIO) and(AMEX: BIOb), a multinational manufacturer and distributor of life scienceresearch and clinical diagnostic products, will report financial resultsfor the first quarter 2008 on Tuesday, May 6, 2008, after the close of themarket. The company will discuss these results in a conference callscheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Apr 11, 2008 - 12:36:01 PM
Public Companies
:
Healthcare/BioTech
RxElite Announces Preferred Contract Status Awarded by National Surgical Hospitals for Their Anesthetic Gas Products
MERIDIAN, ID -- (MARKET WIRE) -- 04/11/08 -- RxElite, Inc. (OTCBB: RXEI) is pleased toannounce the contract award from National Surgical Hospitals, for theiranesthetic gas products. RxElite was awarded a preferred contract listingfor all classes of trade for Sojourn(TM)(Sevoflurane) andTerrell(TM)(Isoflurane). Sevoflurane is most commonly used anesthetic gasin the U.S and Isoflurane continues to hold share in the anesthetic gasmarket.
Apr 11, 2008 - 11:36:03 AM
Public Companies
:
Healthcare/BioTech
WBB Securities Upgrades Cleveland BioLabs to Strong Buy and Reiterates $13 Price Target
BUFFALO, NY -- (MARKET WIRE) -- 04/11/08 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI)announced today that Daniel Mallin, Ph.D. and Stephen Brozak of WBBSecurities, LLC have updated coverage on the Company.
Apr 11, 2008 - 10:36:01 AM
Public Companies
:
Healthcare/BioTech
Endo Announces Executive Appointment
CHADDS FORD, PA -- (MARKET WIRE) -- 04/11/08 -- Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), a market leader in pain management, announced today that IvanGergel, M.D., age 47, has been hired as Executive Vice President, Research& Development. Dr. Gergel is filling a position that has been vacant sinceJune 2007.
Apr 11, 2008 - 8:36:02 AM
Public Companies
:
Healthcare/BioTech
Cavit Sciences, Inc. Announces Production of AMERICARE Supplement Line
MIAMI, FL -- (MARKET WIRE) -- 04/11/08 -- Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT)announced today that production of the AMERICARE supplement line iscommencing. Initially, three products of the AMERICARE line will bemanufactured and marketed. These products are:
Apr 11, 2008 - 8:36:02 AM
Public Companies
:
Healthcare/BioTech
Antisoma announces start of phase III lung cancer trial of ASA404
LONDON, UK -- (MARKET WIRE) -- 04/11/08 --
Apr 11, 2008 - 12:36:01 AM
Public Companies
:
Healthcare/BioTech
Meridian Co., Ltd. Corporate Update
VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 04/10/08 -- Meridian Co., Ltd. (OTCBB: MRDAF) is engaged in the research, development, manufacturing and sales of advanced medical equipment. Meridian would like to take this opportunity to provide a corporate update and to thank its customers and shareholders for their unwavering support and commitment to Meridian over the past several years.
Apr 10, 2008 - 5:36:01 PM
Public Companies
:
Healthcare/BioTech
Bioxel Pharma Inc.: Grant of Options and Deferred Stock Units
SAINTE-FOY, QUEBEC -- (MARKET WIRE) -- 04/10/08 -- Bioxel Pharma Inc.(TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced that, on March 27, 2008, its Board of Directors granted 365,000 common share purchase options to its officers and employees, pursuant to its stock option plan. These options were granted at an exercise price of $0.135 per share, being the closing price of the Corporation's common shares on the TSX Venture Exchange on the last business day preceding the grant date. It should be pointed out that 769,000 options expired between January 1 and April 8, 2008.
Apr 10, 2008 - 4:36:02 PM
Public Companies
:
Healthcare/BioTech
PDL BioPharma Declares $500 Million Special Cash Dividend and Announces Plan to Separate Its Biotechnology Operations From Its Antibody Humanization Royalty Assets
REDWOOD CITY, CA -- (MARKET WIRE) -- 04/10/08 -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI)announced today that its board of directors has:
Apr 10, 2008 - 3:36:01 PM
Public Companies
:
Healthcare/BioTech
MonoGen Announces Facility Approval Delay
LINCOLNSHIRE, ILLINOIS -- (MARKET WIRE) -- 04/10/08 -- MonoGen, Inc. (TSX: MOG) today announced that it has received a letter from the FDA indicating that two of the six responses to observations received during the previously announced inspection of its facilities were not adequate and that a follow up inspection would be required. This letter stems from MonoGen's 180-day PMA Supplement filed with the FDA in October 2007.
Apr 10, 2008 - 2:36:01 PM
Public Companies
:
Healthcare/BioTech
PHC's Pivotal Research Initiates Largest Phase I Alzheimer's Disease Trial to Date for Major National Sponsor
PEABODY, MA -- (MARKET WIRE) -- 04/10/08 -- PHC, Inc. (AMEX: PHC) d.b.a. Pioneer BehavioralHealth, a leading provider of inpatient and outpatient behavioral healthservices and pharmaceutical research, reported that its Pivotal ResearchCenters has initiated its largest Phase I Alzheimer's Disease trial to datefor a major national sponsor.
Apr 10, 2008 - 1:36:04 PM
Public Companies
:
Healthcare/BioTech
Protherics PLC announces Block Listing Return - 1
Cheshire, UK -- (MARKET WIRE) -- 04/10/08 --
Apr 10, 2008 - 1:36:04 PM
Public Companies
:
Healthcare/BioTech
Protherics PLC announces Block Listing Return - 2
Cheshire, UK -- (MARKET WIRE) -- 04/10/08 --
Apr 10, 2008 - 1:36:04 PM
Public Companies
:
Healthcare/BioTech
Protherics PLC announces Block Listing Return - 3
Cheshire, UK -- (MARKET WIRE) -- 04/10/08 --
Apr 10, 2008 - 1:36:04 PM
Public Companies
:
Healthcare/BioTech
Protherics PLC announces Block Listing Return - 4
Cheshire, UK -- (MARKET WIRE) -- 04/10/08 --
Apr 10, 2008 - 1:36:04 PM
Public Companies
:
Healthcare/BioTech
digiMedical Solutions, Inc.(TM) Signs Contract With Dr. Herman L. Spilker in Support of $10 Million 2008 Revenue Goal
COLLEYVILLE, TX -- (MARKET WIRE) -- 04/10/08 -- digiMedical Solutions, Inc. (PINKSHEETS: DGMS) announced today that the Company has signed a contract with Dr.Herman L. Spilker in Naples, Florida, to implement the digiRX system anddigiReauth call center services, which will provide digital prescriptionhandling for his office and will take over the prescription reauthorizationprocessing and refill management services. Dr. Spilker is part of theCollier Heart Group, a high traffic three-physician practice located inNaples, Florida offering comprehensive cardiology care to nearly 100patients a day. Dr. Spilker studied medicine at the University of TexasSouthwestern followed by a three-year fellowship in Cardiovascular Diseaseat Emory University in Atlanta.
Apr 10, 2008 - 9:36:01 AM
Public Companies
:
Healthcare/BioTech
VitalCare Announces Corporate Website
CARSON CITY, NV -- (MARKET WIRE) -- 04/10/08 -- VitalCare Diabetes Treatment Centers, Inc.(PINKSHEETS: VDTI), a Nevada corporation, today announced the completion ofits Corporate Website which will provide up to date information onIntracellular Activation Therapy (iCAT) and a list of all certified andlicensed VitalCare Diabetes Treatment Centers locations. The Website wasdesigned to facilitate information on iCAT Therapy, Treatment Centerlocations, information on VitalCare for investors, and to provide a weblinkto VitalCare's strategic partners' and clinical affiliates' websites, forcurrent information on treatment of Type 1 and Type 2 Diabetes. TheWebsite Address is www.vitalcaretechnology.com.
Apr 10, 2008 - 8:36:01 AM
Public Companies
:
Healthcare/BioTech
China Health Management Corp.: Government of Yunnan Province to Help Support Richland International Hospital as It Develops into a Superior International Medical And Healthcare Services Provider
LAS VEGAS, NEVADA -- (MARKET WIRE) -- 04/10/08 -- China Health Management Corp. (Nevada Company) (PINK SHEETS: CNHC) is pleased to announce that its Richland International Hospital (RIH) has received support from the local Government of Yunnan Province to help develop it into a superior international medical and healthcare services provider.
Apr 10, 2008 - 8:36:01 AM
Public Companies
:
Healthcare/BioTech
Auxilium Pharmaceuticals to Announce First Quarter 2008 Results and Conduct Conference Call on Wednesday, April 30, 2008
MALVERN, PA -- (MARKET WIRE) -- 04/10/08 -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL),a specialty biopharmaceutical company, will release results for the firstquarter 2008 on Wednesday, April 30, 2008 before the opening of thefinancial markets. The Company will also conduct a conference call that dayat 10:00 a.m. ET to discuss results and highlights of the first quarter2008.
Apr 10, 2008 - 8:36:01 AM
Public Companies
:
Healthcare/BioTech
RxElite Announces Preferred Contract Status Awarded for Their Anesthetic Gas Products by Nueterra Healthcare
MERIDIAN, ID -- (MARKET WIRE) -- 04/10/08 -- RxElite, Inc. (OTCBB: RXEI) is pleased toannounce that it has been selected by Nueterra Healthcare as a "preferredsupplier" to supply Nueterra Healthcare with anesthetic gas products.Effective February 8, 2008, RxElite was awarded the contract listing forall classes of trade for Sojourn(TM) (Sevoflurane) and Terrell(TM)(Isoflurane). Sevoflurane is the most commonly used anesthetic gas in theUnited States and Isoflurane continues to be used widely in anesthesiapractice.
Apr 10, 2008 - 8:36:01 AM
Public Companies
:
Healthcare/BioTech
Symbollon Pharmaceuticals Announces Results of IoGen Phase III Clinical Trial
FRAMINGHAM, MA -- (MARKET WIRE) -- 04/10/08 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced the results of a Phase III clinical trial designedto evaluate the effectiveness of IoGen™ for the treatment of moderate tosevere cyclic pain associated with fibrocystic breast disease. In thestudy, patients were dosed once a day for up to six months with either a6-mg IoGen tablet or placebo. There was no statistically significantdifference between the treatment groups on the primary endpoint of painreduction. The findings demonstrated equivalence between the active6-mg IoGen formulation and the placebo in achieving the primary efficacyendpoint. The data also showed no statistically significant differencebetween the two groups in achieving the secondary efficacy endpoint offibrosis reduction. The overall incidence rates of treatment-relatedadverse events, serious adverse events or adverse events leading todiscontinuation were generally similar between treatment groups.
Apr 10, 2008 - 8:36:01 AM
Public Companies
:
Healthcare/BioTech
Endo Pharmaceuticals Holdings Inc. Prices Private Offering of Convertible Senior Subordinated Notes
CHADDS FORD, PA -- (MARKET WIRE) -- 04/10/08 -- Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) today announced the pricing of its offering of $345 million aggregateprincipal amount of 1.75% convertible senior subordinated notes due 2015 toqualified institutional buyers in accordance with Rule 144A under theSecurities Act of 1933, as amended (the "Securities Act"). In addition,Endo announced that the initial purchasers have exercised in full theiroption to purchase up to an additional $34.5 million in aggregate principalamount of notes to cover overallotments, resulting in the sale of $379.5million total aggregate principal amount of notes in the offering. Thecoupon on the notes will be 1.75% per year on the principal amount fromApril 15, 2008, payable semi-annually in arrears. Endo will be permittedto deliver cash, shares of Endo common stock or a combination of cash andshares, at Endo's election, to satisfy any future conversions of the notes.It is Endo's current intent to settle the principal amount of anyconversion consideration in cash. The initial conversion rate for the noteswill be approximately 34.2466 shares of Endo common stock per $1,000principal amount of notes, which is equivalent to the initial conversionprice of $29.20 per share of common stock and represents a 17.5% conversionpremium over the last reported sale price of Endo's common stock on April9, 2008, which was $24.85 per share. The conversion rate and the conversionprice will be subject to adjustment in certain events, such asdistributions of dividends or stock splits. The transaction is expected toclose on or about April 15, 2008, subject to the satisfaction of variouscustomary closing conditions.
Apr 10, 2008 - 7:36:02 AM
Public Companies
:
Healthcare/BioTech
ART Advanced Research Technologies to Present Molecular Imaging Products at AACR Meeting in San Diego
MONTREAL, CANADA -- (MARKET WIRE) -- 04/10/08 -- ART Advanced Research Technologies Inc. ("ART")(TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be exhibiting at the Annual Meeting of the American Association for Cancer Research (AACR), April 13-16, in San Diego, CA. ART will showcase its preclinical product offering, including current research in the oncological and pharmacokinetics fields using the Optix® MX2 optical imaging device, as well as the Fenestra® line of contrast agents for microCT imaging, at its booth (#1007) located in the San Diego Convention Center.
Apr 10, 2008 - 7:36:02 AM
Public Companies
:
Healthcare/BioTech
Biolase Announces Global Launch of Endolase(TM) RFT Root Canal Therapy System for Waterlase(R) MD Laser System
IRVINE, CA -- (MARKET WIRE) -- 04/10/08 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), theworld's leading dental laser company, announced today the global launch ofits new, minimally invasive Endolase(TM) RFT Root Canal Therapy System,which enables endodontists and dentists to perform root canal proceduresfaster and more effectively than conventional treatment methods. EndolaseRFT includes two newly designed, single-use laser tips, calledendoTips(TM), and the procedure protocol for use with the Company'sWaterlase® MD YSGG laser system. In March of this year, the Companyreceived U.S. Food and Drug Administration (FDA) 510(k) clearance of itsWaterlase MD with RFT endoTips for root canal disinfection after endodonticinstrumentation, making BIOLASE the first company to receive clearancesthat allow dentists to treat infected, painful toothaches with advancedlaser technology.
Apr 10, 2008 - 5:36:01 AM
Public Companies
:
Healthcare/BioTech
Reputable Immunologist Joins Scientific Advisory Board at NextGen
LONDON, UNITED KINGDOM -- (MARKET WIRE) -- 04/10/08 -- NextGen Bioscience, Inc. ("NextGen") (PINK SHEETS: NXGB), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced that Professor William H. Stimson of Scotland is joining its International Scientific Advisory Board.
Apr 10, 2008 - 5:36:01 AM
Public Companies
:
Healthcare/BioTech
Post-Exposure Vaccination With IMVAMUNE(R) Protects Against Lethal Poxvirus Infection
COPENHAGEN, DENMARK -- (MARKET WIRE) -- 04/10/08 -- In studies with Bavarian Nordic's newand innovative third-generation smallpox vaccine, IMVAMUNE®, scientistsfrom Bavarian Nordic have for the first time demonstrated a therapeuticeffect of a smallpox vaccine, days after infection. With the currentavailable first- and second-generation smallpox vaccines no evidence of atherapeutic effect has ever been shown in animal models. This discovery wasrecently published in the prestigious Journal of Clinical Investigation.
Apr 10, 2008 - 3:36:01 AM
Public Companies
:
Healthcare/BioTech
Bausch & Lomb and Galapagos sign agreement to collaborate on ophthalmic disease research
MECHELEN, BELGIUM -- (MARKET WIRE) -- 04/10/08 --
Apr 10, 2008 - 1:36:01 AM
Public Companies
:
Healthcare/BioTech
Endoscopy Study Concludes PillCam(R) COLON May Be a Cost-Effective Strategy for Preventing Colo-Rectal Cancer
YOQNEAM, ISRAEL -- (MARKET WIRE) -- 04/10/08 -- Given Imaging Ltd. (NASDAQ: GIVN) todayannounced a study in the May issue of Endoscopy found PillCam® COLON tobe a cost-effective approach to preventing colo-rectal cancer (CRC) whenused in the average-risk, general population that fails to comply withcurrent CRC screening guidelines. The aim of the analysis was to provide amodel to assess the cost and effectiveness of population-based screeningfor CRC using capsule endoscopy compared with that of a standardcolonoscopy screening program. The study was conducted by Professor CesareHassan, M.D. of the Gastroenterology and Digestive Endoscopy Unit of theNuovo Regina Margherita Hospital in Rome.
Apr 10, 2008 - 12:36:01 AM
Public Companies
:
Healthcare/BioTech
Bioxel Pharma: Fiscal 2007 Results
SAINTE-FOY, QUEBEC -- (MARKET WIRE) -- 04/09/08 -- Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced its results for the fourth quarter and the fiscal year ended December 31, 2007.
Apr 9, 2008 - 4:36:01 PM
Public Companies
:
Healthcare/BioTech
Medical Institutional Services Holdings Signs Contract With Doctors Family Medical Centers
FORT LAUDERDALE, FL -- (MARKET WIRE) -- 04/09/08 -- Medical Institutional ServicesHoldings, Inc. (PINKSHEETS: MIHS) (MIHS) is proud to announce that it hassigned a contract with primary care facility Doctors Family MedicalCenters. Located in Tampa, Florida, the centers are expanding state wideunder the direction of medical director Morayma Martinez, MD. The contractwill generate approximately $100,000 in revenues for MIHS. "As DoctorsFamily grows, so will the orders that they will be placing within ouronline ordering system. We are very excited with this contract, consideringthe anticipated growth of Doctors Family," said Ron Berman MIHS President.MIHS continues to expand and with the signing of each contract itsreputation will be further branded throughout the health care industry. Thehighly recognized features of the MIHS business model are leading thiscompany to new levels of expertise in the distribution of medical supplies.
Apr 9, 2008 - 3:36:01 PM
Public Companies
:
Healthcare/BioTech
Endo Pharmaceuticals Holdings Inc. Announces Stock Repurchase Program and Proposed Private Offering of Convertible Senior Subordinated Notes
CHADDS FORD, PA -- (MARKET WIRE) -- 04/09/08 -- Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) announced today that its Board of Directors has approved a sharerepurchase program, authorizing Endo to repurchase in the aggregate up to$750 million of shares of its outstanding common stock. Purchases by Endounder this program may be made from time to time in open market purchases,privately negotiated transactions, accelerated stock repurchasetransactions or otherwise, as determined by Endo.
Apr 9, 2008 - 3:36:01 PM
|
|
|
|
